NASDAQ:GH - Guardant Health Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$51.07 +2.20 (+4.50 %)
(As of 02/18/2019 03:56 PM ET)
Previous Close$48.87
Today's Range$49.2497 - $52.13
52-Week Range$27.04 - $52.13
Volume802,444 shs
Average Volume363,428 shs
Market Capitalization$4.38 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Receive GH News and Ratings via Email

Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone855-698-8887

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees348
Market Cap$4.38 billion
OptionableNot Optionable

Guardant Health (NASDAQ:GH) Frequently Asked Questions

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release their next quarterly earnings announcement on Monday, February 18th 2019. View Earnings Estimates for Guardant Health.

What price target have analysts set for GH?

5 Wall Street analysts have issued 12-month target prices for Guardant Health's shares. Their predictions range from $37.00 to $42.00. On average, they anticipate Guardant Health's stock price to reach $39.50 in the next twelve months. This suggests that the stock has a possible downside of 22.7%. View Analyst Price Targets for Guardant Health.

What is the consensus analysts' recommendation for Guardant Health?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Guardant Health.

Has Guardant Health been receiving favorable news coverage?

News headlines about GH stock have trended positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Guardant Health earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term.

Who are some of Guardant Health's key competitors?

Who are Guardant Health's key executives?

Guardant Health's management team includes the folowing people:
  • Mr. AmirAli Talasaz, Chairman, Pres & COO (Age 40)
  • Dr. Helmy Eltoukhy Ph.D., Co-Founder, CEO & Director (Age 40)
  • Mr. Michael J. Wiley, Chief Legal Officer (Age 44)
  • Mr. Derek A. Bertocci, Chief Financial Officer (Age 65)
  • Dr. Richard B. Lanman, Chief Medical Officer (Age 64)

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

When does Guardant Health's lock-up period expire?

Guardant Health's lock-up period expires on Tuesday, April 2nd. Guardant Health had issued 12,500,000 shares in its public offering on October 4th. The total size of the offering was $237,500,000 based on an initial share price of $19.00. After the end of Guardant Health's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by many different of institutional and retail investors. Top institutional investors include Temasek Holdings Private Ltd (1.88%), Orbimed Advisors LLC (1.79%), BlackRock Inc. (1.30%), Jennison Associates LLC (0.98%), Lord Abbett & CO. LLC (0.62%) and Massachusetts Financial Services Co. MA (0.53%).

Which major investors are buying Guardant Health stock?

GH stock was bought by a variety of institutional investors in the last quarter, including Temasek Holdings Private Ltd, Orbimed Advisors LLC, BlackRock Inc., Jennison Associates LLC, Lord Abbett & CO. LLC, Massachusetts Financial Services Co. MA, Geode Capital Management LLC and Northern Trust Corp.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $51.07.

How big of a company is Guardant Health?

Guardant Health has a market capitalization of $4.38 billion. Guardant Health employs 348 workers across the globe.

What is Guardant Health's official website?

The official website for Guardant Health is http://www.guardanthealth.com.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 Penobscot Dr., Redwood City CA, 94063. The company can be reached via phone at 855-698-8887.


MarketBeat Community Rating for Guardant Health (NASDAQ GH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  98
MarketBeat's community ratings are surveys of what our community members think about Guardant Health and other stocks. Vote "Outperform" if you believe GH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Featured Article: Lock-Up Period Expiration

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel